vs
Side-by-side financial comparison of ACADIA PHARMACEUTICALS INC (ACAD) and BJs RESTAURANTS INC (BJRI). Click either name above to swap in a different company.
BJs RESTAURANTS INC is the larger business by last-quarter revenue ($355.4M vs $284.0M, roughly 1.3× ACADIA PHARMACEUTICALS INC). ACADIA PHARMACEUTICALS INC runs the higher net margin — 96.3% vs 3.6%, a 92.8% gap on every dollar of revenue. On growth, ACADIA PHARMACEUTICALS INC posted the faster year-over-year revenue change (9.4% vs 3.2%). Over the past eight quarters, ACADIA PHARMACEUTICALS INC's revenue compounded faster (17.5% CAGR vs 2.6%).
Acadia Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Del Mar, San Diego, California.
BJ's Restaurants Inc. operates a chain of casual dining restaurants across the United States. Its menu features signature deep-dish pizzas, craft beers, handcrafted cocktails, and a wide range of American comfort food. The brand primarily serves family groups, friend gatherings, and casual diners seeking affordable, high-quality meals in a relaxed, welcoming in-store environment.
ACAD vs BJRI — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $284.0M | $355.4M |
| Net Profit | $273.6M | $12.6M |
| Gross Margin | 90.8% | 74.5% |
| Operating Margin | 6.1% | 3.1% |
| Net Margin | 96.3% | 3.6% |
| Revenue YoY | 9.4% | 3.2% |
| Net Profit YoY | 90.3% | -24.2% |
| EPS (diluted) | $1.61 | $0.58 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $284.0M | $355.4M | ||
| Q3 25 | $278.6M | $365.6M | ||
| Q2 25 | $264.6M | $348.0M | ||
| Q1 25 | $244.3M | — | ||
| Q4 24 | $259.6M | $325.7M | ||
| Q3 24 | $250.4M | $349.9M | ||
| Q2 24 | $242.0M | $337.3M | ||
| Q1 24 | $205.8M | — |
| Q4 25 | $273.6M | $12.6M | ||
| Q3 25 | $71.8M | $22.2M | ||
| Q2 25 | $26.7M | $13.5M | ||
| Q1 25 | $19.0M | — | ||
| Q4 24 | $143.7M | $-2.9M | ||
| Q3 24 | $32.8M | $17.2M | ||
| Q2 24 | $33.4M | $7.7M | ||
| Q1 24 | $16.6M | — |
| Q4 25 | 90.8% | 74.5% | ||
| Q3 25 | 92.2% | 75.2% | ||
| Q2 25 | 92.2% | 75.0% | ||
| Q1 25 | 91.7% | — | ||
| Q4 24 | 91.6% | 73.4% | ||
| Q3 24 | 92.5% | 74.3% | ||
| Q2 24 | 92.5% | 74.8% | ||
| Q1 24 | 88.8% | — |
| Q4 25 | 6.1% | 3.1% | ||
| Q3 25 | 12.8% | 5.8% | ||
| Q2 25 | 12.2% | 4.3% | ||
| Q1 25 | 7.9% | — | ||
| Q4 24 | 59.1% | -0.8% | ||
| Q3 24 | 12.6% | 3.8% | ||
| Q2 24 | 12.6% | 2.4% | ||
| Q1 24 | 7.4% | — |
| Q4 25 | 96.3% | 3.6% | ||
| Q3 25 | 25.8% | 6.1% | ||
| Q2 25 | 10.1% | 3.9% | ||
| Q1 25 | 7.8% | — | ||
| Q4 24 | 55.4% | -0.9% | ||
| Q3 24 | 13.1% | 4.9% | ||
| Q2 24 | 13.8% | 2.3% | ||
| Q1 24 | 8.0% | — |
| Q4 25 | $1.61 | $0.58 | ||
| Q3 25 | $0.42 | $0.97 | ||
| Q2 25 | $0.16 | $0.58 | ||
| Q1 25 | $0.11 | — | ||
| Q4 24 | $0.86 | $-0.13 | ||
| Q3 24 | $0.20 | $0.72 | ||
| Q2 24 | $0.20 | $0.32 | ||
| Q1 24 | $0.10 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $177.7M | $23.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.2B | $366.2M |
| Total Assets | $1.6B | $1.0B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $177.7M | $23.8M | ||
| Q3 25 | $258.0M | $26.0M | ||
| Q2 25 | $253.6M | $19.0M | ||
| Q1 25 | $217.7M | — | ||
| Q4 24 | $319.6M | $18.4M | ||
| Q3 24 | $155.1M | $16.2M | ||
| Q2 24 | $177.1M | $18.8M | ||
| Q1 24 | $204.7M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | $60.5M | ||
| Q2 25 | — | $85.5M | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $66.5M | ||
| Q3 24 | — | $63.5M | ||
| Q2 24 | — | $58.0M | ||
| Q1 24 | — | — |
| Q4 25 | $1.2B | $366.2M | ||
| Q3 25 | $917.3M | $386.6M | ||
| Q2 25 | $822.4M | $371.5M | ||
| Q1 25 | $765.2M | — | ||
| Q4 24 | $732.8M | $376.2M | ||
| Q3 24 | $577.2M | $386.5M | ||
| Q2 24 | $516.7M | $375.4M | ||
| Q1 24 | $464.0M | — |
| Q4 25 | $1.6B | $1.0B | ||
| Q3 25 | $1.3B | $1.0B | ||
| Q2 25 | $1.2B | $1.0B | ||
| Q1 25 | $1.1B | — | ||
| Q4 24 | $1.2B | $1.0B | ||
| Q3 24 | $976.9M | $1.0B | ||
| Q2 24 | $914.1M | $1.0B | ||
| Q1 24 | $855.1M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | 0.16× | ||
| Q2 25 | — | 0.23× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.18× | ||
| Q3 24 | — | 0.16× | ||
| Q2 24 | — | 0.15× | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-48.7M | — |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | -0.18× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-48.7M | — | ||
| Q3 25 | $74.3M | $62.3M | ||
| Q2 25 | $64.0M | $4.6M | ||
| Q1 25 | $20.3M | — | ||
| Q4 24 | $40.4M | $27.3M | ||
| Q3 24 | $63.2M | $20.2M | ||
| Q2 24 | $25.0M | $22.3M | ||
| Q1 24 | $29.1M | — |
| Q4 25 | — | — | ||
| Q3 25 | $73.9M | $41.9M | ||
| Q2 25 | — | $-12.1M | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $7.6M | ||
| Q3 24 | $63.2M | $735.0K | ||
| Q2 24 | — | $448.0K | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | 26.5% | 11.5% | ||
| Q2 25 | — | -3.5% | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 2.3% | ||
| Q3 24 | 25.2% | 0.2% | ||
| Q2 24 | — | 0.1% | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | 0.1% | 5.6% | ||
| Q2 25 | — | 4.8% | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 6.0% | ||
| Q3 24 | 0.0% | 5.6% | ||
| Q2 24 | — | 6.5% | ||
| Q1 24 | — | — |
| Q4 25 | -0.18× | — | ||
| Q3 25 | 1.03× | 2.80× | ||
| Q2 25 | 2.40× | 0.34× | ||
| Q1 25 | 1.07× | — | ||
| Q4 24 | 0.28× | — | ||
| Q3 24 | 1.93× | 1.18× | ||
| Q2 24 | 0.75× | 2.89× | ||
| Q1 24 | 1.76× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ACAD
| Nuplazid | $174.4M | 61% |
| Daybue | $109.6M | 39% |
BJRI
Segment breakdown not available.
